Tyra Biosciences (TYRA) Operating Expenses (2020 - 2026)

Tyra Biosciences has reported Operating Expenses for 7 years, with the latest figure at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 31.86% year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at $142.9 million (up 25.66% YoY), and the FY2025 full-year result was $132.8 million, up 27.44% from the prior year.
• Operating Expenses for Q1 2026 stood at $42.0 million, up from $36.5 million in the prior quarter.
• The five-year high for Operating Expenses was $42.0 million in Q1 2026, with the low at $13.6 million in Q3 2022.
• Historically, Operating Expenses has averaged $24.6 million across 5 years, with a median of $24.0 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 252.27% — and 2023, when it fell 3.37%.
• Tyra Biosciences' Operating Expenses stood at $15.0 million in 2022, then soared by 70.69% to $25.6 million in 2023, then increased by 16.03% to $29.7 million in 2024, then gained by 22.77% to $36.5 million in 2025, then advanced by 15.01% to $42.0 million in 2026.
• The last three Operating Expenses figures came in at $42.0 million (Q1 2026), $36.5 million (Q4 2025), and $32.9 million (Q3 2025), per Business Quant data.